Zinger Key Points
- Invivyd secures $30M term loan facility with SVB, enabling future capital drawdowns.
- Loan supports key milestones, including FDA alignment on VYD2311 regulatory pathway.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Invivyd, Inc. IVVD shares gained in the premarket session on Monday after the company disclosed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank.
The agreement enables future capital drawdowns upon meeting specific conditions and milestones.
Bill Duke, Chief Financial Officer of Invivyd, said, “We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the regulatory pathway of our pipeline candidate, VYD2311,”
Last month, the company reported an FY24 EPS loss of $(1.43), beating the consensus of $(1.48), and sales of $25.38 million exceeded the street view of $25.15 million.
As of December 31, 2024, cash and cash equivalents stood at $69.3 million.
Invivyd aims to achieve near-term profitability by the end of the fi rst half of 2025, leveraging its existing cash reserves, expected growth in net product revenue, and ongoing reduction in manufacturing costs.
Price Action: IVVD shares are down 0.78% at $0.50 at the last check on Monday.
Read Next:
Photo Courtesy: tadamichi on Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.